Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lipocine (LPCN) EPS (Basic) (2016 - 2025)

Lipocine (LPCN) has disclosed EPS (Basic) for 13 consecutive years, with -$0.59 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Basic) fell 43.9% year-over-year to -$0.59, compared with a TTM value of -$1.76 through Sep 2025, down 134.67%, and an annual FY2024 reading of $0.0, up 100.05% over the prior year.
  • EPS (Basic) was -$0.59 for Q3 2025 at Lipocine, down from -$0.41 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.66 in Q1 2024 and bottomed at -$1.26 in Q3 2023.
  • Average EPS (Basic) over 5 years is -$0.34, with a median of -$0.41 recorded in 2025.
  • The sharpest move saw EPS (Basic) surged 333.33% in 2021, then plummeted 1750.0% in 2023.
  • Year by year, EPS (Basic) stood at $0.14 in 2021, then tumbled by 407.14% to -$0.43 in 2022, then rose by 2.33% to -$0.42 in 2023, then skyrocketed by 180.08% to $0.34 in 2024, then crashed by 275.41% to -$0.59 in 2025.
  • Business Quant data shows EPS (Basic) for LPCN at -$0.59 in Q3 2025, -$0.41 in Q2 2025, and -$0.35 in Q1 2025.